These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8960273)

  • 21. Stability of cephalosporin prodrug esters in human intestinal juice: implications for oral bioavailability.
    Stoeckel K; Hofheinz W; Laneury JP; Duchene P; Shedlofsky S; Blouin RA
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2602-6. PubMed ID: 9756762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intestinal transport of cefuroxime axetil in rats: absorption and hydrolysis processes.
    Ruiz-Balaguer N; Nacher A; Casabo VG; Merino Sanjuan M
    Int J Pharm; 2002 Mar; 234(1-2):101-11. PubMed ID: 11839441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical studies on cefuroxime axetil in acute mastitis].
    Nakamura T; Hashimoto I; Sawada Y; Mikami J
    Jpn J Antibiot; 1987 Feb; 40(2):340-8. PubMed ID: 3599383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Stepwise therapy of community-acquired pneumonia. Results of cefuroxime and cefuroxime axetil study].
    Iakovlev SV; Suvorova MP; Dvoretskiĭ LI; Vlasenko NA; Shakhova TV
    Antibiot Khimioter; 1998; 43(6):7-11. PubMed ID: 9644527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of two types of Indian breakfast on bioavailability of cefuroxime axetil.
    Vasu S; Adithan C; Shashindran CH; Asad M; Koumaravelou K; Topno I
    Indian J Med Res; 2000 Sep; 112():104-8. PubMed ID: 11094856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of dose and food on the bioavailability of cefuroxime axetil.
    Finn A; Straughn A; Meyer M; Chubb J
    Biopharm Drug Dispos; 1987; 8(6):519-26. PubMed ID: 3427209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and absolute bioavailability of oral cefuroxime axetil in the rat.
    Ruiz-Carretero P; Nacher A; Merino-Sanjuan M; Casabo VG
    Int J Pharm; 2000 Jul; 202(1-2):89-96. PubMed ID: 10915930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of the in vitro activity of a new cephalosporin, cefuroxime, and cephalothin against 810 clinical isolates.
    Skar AG; Midtvedt T; Dahl O
    NIPH Ann; 1979 Dec; 2(2):31-40. PubMed ID: 398460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonlinear intestinal absorption kinetics of cefuroxime axetil in rats.
    Ruiz-Balaguer N; Nacher A; Casabo VG; Merino M
    Antimicrob Agents Chemother; 1997 Feb; 41(2):445-8. PubMed ID: 9021205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absorption of ester prodrugs in Caco-2 and rat intestine models.
    He X; Sugawara M; Takekuma Y; Miyazaki K
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2604-9. PubMed ID: 15215116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and biological activity of novel 3-(2-propenyl)-cephalosporins. II. Preparation of prodrugs.
    Kim WJ; Ko KY; Jung MH; Kim M; Lee KI; Kim JH
    J Antibiot (Tokyo); 1991 Oct; 44(10):1083-7. PubMed ID: 1955390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New special agents registered in Austria. Zinnat (cefuroxime axetil, glaxo)].
    Gartler W
    Wien Klin Wochenschr; 1991; 103(10):306-12. PubMed ID: 1858381
    [No Abstract]   [Full Text] [Related]  

  • 33. PBP binding and periplasmic concentration as determinants of the antibacterial activities of three new oral cephalosporins in Escherichia coli.
    Cornaglia G; Ligozzi M; Bauernfeind A; Satta G; Fontana R
    New Microbiol; 1994 Jul; 17(3):203-10. PubMed ID: 7968655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative investigations on the bioavailability of cefuroxime axetil.
    Kees F; Lukassek U; Naber KG; Grobecker H
    Arzneimittelforschung; 1991 Aug; 41(8):843-6. PubMed ID: 1781808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment.
    Brink HS; Huisman RM; Geerlings W; de Jong PE
    Adv Perit Dial; 1994; 10():179-82. PubMed ID: 7999822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefuroxime axetil.
    Emmerson AM
    J Antimicrob Chemother; 1988 Aug; 22(2):101-4. PubMed ID: 3053551
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.
    Garton AM; Rennie RP; Gilpin J; Marrelli M; Shafran SD
    J Antimicrob Chemother; 1997 Dec; 40(6):903-6. PubMed ID: 9462447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and bioavailability of oral cephalosporins, KR-984055 and its prodrugs, KR-999001 and KR-999002, in the rat.
    Park YS; Woo SK; Jung MH; Kwon KI
    Arch Pharm Res; 2003 Jan; 26(1):83-8. PubMed ID: 12568364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative staphylolytic activity of cefoxitin, cephalothin and cefuroxime.
    Rogers DT; Russell AD
    J Antimicrob Chemother; 1980 Jul; 6(4):511-7. PubMed ID: 7430014
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers.
    Harding SM; Williams PE; Ayrton J
    Antimicrob Agents Chemother; 1984 Jan; 25(1):78-82. PubMed ID: 6703686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.